Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial

Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial

JUMP is a phase 3b expanded-access trial for patients without access to ruxolitinib outside of a clinical study; it is the largest clinical trial to date in patients with myelofibrosis who have been treated with ruxolitinib. Here, we present safety and efficacy findings from an analysis of 1144 pati...

Full description

Bibliographic Details
Main Authors: Haifa Kathrin Al-Ali, Martin Griesshammer, Philipp le Coutre, Cornelius F. Waller, Anna Marina Liberati, Philippe Schafhausen, Renato Tavares, Pilar Giraldo, Lynda Foltz, Pia Raanani, Vikas Gupta, Bayane Tannir, Julian Perez Ronco, Jagannath Ghosh, Bruno Martino, Alessandro M. Vannucchi
Format: Article
Language:English
Published: Ferrata Storti Foundation 2016-09-01
Series:Haematologica
Online Access:https://haematologica.org/article/view/7819

Internet

https://haematologica.org/article/view/7819

Similar Items